issuer: SYGNIS Pharma AG Im Neuenheimer Feld 515 D-69120 Heidelberg phone: +49 (0)6221 454-6 FAX: +49 (0)6221 454-777 mail: contact@sygnis.de WWW: http://www.sygnis.de sector: Biotechnology ISIN: DE000A1E9B74 indexes: CDAX, Prime All Share stockmarkets: regulated dealing/prime standard: Frankfurt, free trade: ...
Contact: Dr. Franz-Werner Haas Senior Vice President Operations +49 (0) 6221 454 812 franz-werner.haas@sygnis.de Branche: Biotechnology ISIN: DE000A1E9B74 WKN: A1E9B7 Index: CDAX, Prime All Share Börsen: Frankfurt / regulated dealing/prime standard Berlin / free trade Hamburg / free trade Stuttgart / free trade ...
Contact: Dr. Franz-Werner Haas Senior Vice President Operations +49 (0) 6221 454 812 franz-werner.haas@sygnis.de Branche: Biotechnology ISIN: DE000A1E9B74 WKN: A1E9B7 Index: CDAX, Prime All Share Börsen: Frankfurt / regulated dealing/prime standard Berlin / free trade Hamburg / free trade Stuttgart / free trade ...
Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. quarterly report Heidelberg (euro adhoc) - SYGNIS announces nine month results of fiscal year 2010/2011 Heidelberg, 14 February 2011 - SYGNIS Pharma AG (Frankfurt: LIOK; ISIN DE000A1E9B74; Prime Standard) today published its ...
Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. Licensing Agreements Heidelberg (euro adhoc) - SYGNIS strengthens patent position on AX200 for the treatment of neurodegenerative diseases Heidelberg, 09 February 2011 - SYGNIS ...
Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. Research & Development Heidelberg (euro adhoc) - SYGNIS announces Data Safety Monitoring Board Recommendation for Phase II efficacy study for AX200 - more than 50% of the AXIS ...
Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. Capital measures Heidelberg (euro adhoc) - SYGNIS´ reduction of share capital in a 3:1 ratio was entered in the commercial register Heidelberg, 15 December 2010 - SYGNIS Pharma ...
Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. 6-month report Heidelberg (euro adhoc) - SYGNIS announces six month results of fiscal year 2010/2011 Heidelberg, 11 November 2010 - SYGNIS Pharma AG (Frankfurt: LIO; ISIN DE0005043509; Prime Standard) today published its ...
ad-hoc disclosure pursuant to section 15 of the WpHG transmitted by euro adhoc with the aim of a Europe-wide distribution. The issuer is solely responsible for the content of this announcement. Company Information 29.10.2010 Ad-hoc SYGNIS Pharma AG announces strategic restructuring Heidelberg, 29 October 2010 - SYGNIS Pharma AG (Frankfurt: LIO; ISIN DE0005043509; Prime Standard) announced today a ...
ad-hoc disclosure pursuant to section 15 of the WpHG transmitted by euro adhoc with the aim of a Europe-wide distribution. The issuer is solely responsible for the content of this announcement. C.E.O. Interviews 28.10.2010 Ad-hoc Dr. Alfred Bach resigns as CEO of SYGNIS Pharma AG Heidelberg, 28 October 2010 - SYGNIS Pharma AG (Frankfurt: LIO; ISIN DE0005043509; Prime Standard) announced today that the ...
Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. Annual & Special Corporate Meetings Heidelberg (euro adhoc) - Press Release Heidelberg, October 20, 2010 - SYGNIS Pharma AG (Frankfurt: LIO; ISIN DE0005043509; Prime ...
Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. 3-month report Heidelberg (euro adhoc) - Press release Heidelberg, August 12, 2010 - SYGNIS Pharma AG (Frankfurt: LIO; ISIN DE0005043509; Prime Standard) today reports financial results for the first quarter of the fiscal ...
Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. annual report Heidelberg (euro adhoc) - Heidelberg, 29 June 2010 - SYGNIS Pharma AG (Frankfurt: LIO; ISIN DE0005043509; Prime Standard) today announced its financial results for the 2009/2010 fiscal year, which ended on 31 March ...
Heidelberg (ots) - SYGNIS Pharma AG (Frankfurt: LIO; ISIN DE0005043509; Prime Standard) today reports financial results for the third quarter and the first nine months of the fiscal year 2009/2010 ended December 31, 2009. Financials - Cash including marketable securities amounted to EUR16.4 million as of December 31, 2009 (EUR26.0 million Q3 2008/2009). Long term financial liabilities ...
Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. Accounting and Audits/Company Information/Financial Figures/Balance Sheet/quarterly report/6-month report Heidelberg (euro adhoc) - Heidelberg, November 10, 2009 - SYGNIS Pharma AG (Frankfurt: LIO; ISIN DE0005043509; Prime Standard) today ...
ad-hoc disclosure pursuant to section 15 of the WpHG transmitted by euro adhoc with the aim of a Europe-wide distribution. The issuer is solely responsible for the content of this announcement. Company Information 19.10.2009 Heidelberg, 19 October 2009 - SYGNIS Pharma AG (Frankfurt: LIO; ISIN ...
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. Receipt of mandatory offer 14.11.2008 Ad Hoc Heidelberg, 14 November 2008 - SYGNIS Pharma AG (Frankfurt: LIO; ISIN DE0005043509; Prime Standard) has been informed today that dievini Hopp ...
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. 15.10.2008 SYGNIS Pharma AG Approves Capital Increase Heidelberg, October 15, 2008 - Today the Management Board of the Heidelberg biotechnology company SYGNIS Pharma AG (Frankfurt: LIO; ISIN ...
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. Research & Development 22.07.2007 Heidelberg, July 22nd, 2007 - SYGNIS Pharma AG has successfully completed the clinical phase IIa-study (AXIS) in stroke. AXIS was a multicenter, ...
Announcement on Publication of Financial Reports SYGNIS Pharma AG announces today that the following financial reports will be published in the Fiscal Year 2007/2008: 1. Consolidated interim financial statement as of June 30th, 2007("3-Months-Report") will be released on August 14th, 2007 2. Consolidated interim ...
SYGNIS Pharma announces that the Annual Report for the Financial Year 2006/2007 will be published on 28.06.2007. Tip announcement for financial statements transmitted by euro adhoc. The issuer is responsible for the content of this announcement. The financial statement is available: in the internet at: ...
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. 20.10.2006 Heidelberg, October 20, 2006 - LION bioscience AG received today an adjustment of the voluntary take-over bid to the LION shareholders by the two investment- companies of the Hopp ...
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. 09.10.2006 Heidelberg, October 9, 2006 - After successful completion of the capital increase in connection with the acquisition of SYGNIS Bioscience GmbH & Co. KG, the Supervisory Board ...
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. 05.07.2006 Heidelberg, July 5, 2006 - LION bioscience received today the information that two investment-companies of the Hopp family, DH-Capital GmbH & Co. KG und OH Beteiligungen GmbH & ...
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. 05.07.2006 Heidelberg, July 5, 2006 - With the sale of its bioinformatics business unit in March this year, LION bioscience AG disposed most of its operational business and, thereby, reached ...
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. 04.04.2006 Ad-hoc Release LION bioscience sells bioinformatics business Dr. Thure Etzold resigns as CEO Heidelberg, April 4, 2006 - LION bioscience AG today announced the successful ...
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. 24.03.2005 In todays extraordinary shareholders meeting the shareholder Ian Humphrey-Smith informed the audience and LION bioscience AG about a likely non-binding and non-specific take-over ...
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. 14.02.2005 Cambridge, MA, USA, Heidelberg, Germany, February 14, 2005 - LION bioscience today announced there will be an extraordinary shareholder meeting on March 24, 2005. The reason for the ...
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. Cambridge, MA, USA, Heidelberg, Germany, November 18, 2004 - LION bioscience AG (Nasdaq: LEON) today announced that the recently appointed Supervisory Board of LION bioscience AG has ...
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. Cambridge, MA, USA, Heidelberg, Germany, November 17, 2004 - The Supervisory Board of LION bioscience AG has reappointed LION´s Executive Board with immediate effect. Dr. Thure Etzold was ...